• 1
    Piddock LJ. Mechanisms of fluoroquinolone resistance: an update 1994–1998. Drugs 1999; 58(suppl 2): S11S18.
  • 2
    Weigel LM, Steward CD, Tenover FC. gyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae. Antimicrob Agents Chemother 1998; 42: 26612667.
  • 3
    Garau J, Xercavins M, Rodriguez-Carballeira M et al. Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother 1999; 43: 27362741.
  • 4
    McDonald LC, Chen FJ, Lo HJ et al. Emergence of reduced susceptibility and resistance to fluoroquinolones in Escherichia coli in Taiwan and contributions of distinct selective pressures. Antimicrob Agents Chemother 2001, 45: 30843091.
  • 5
    Vatopoulos AC, Kalapothaki V, The Greek Network for the Surveillance of Antimicrobial Resistance, Legakis NJ. Trends in bacterial resistance to ciprofloxacin in Greece. Results from the Greek National Electronic Surveillance System. Emerg Infect Dis 1999; 5: 471476.
  • 6
    Vatopoulos AC, Kalapothaki V, Legakis NJ, the Greek Network for the Surveillance of Antimicrobial Resistance. An electronic network for the surveillance of antimicrobial resistance in bacterial nosocomial isolates in Greece. Bull WHO 1999; 77: 595601.
  • 7
    National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility testing, 7th edn. Document M2-A7. Wayne, PA: NCCLS, 2000.
  • 8
    National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th edn. Approved standard M7-A5. Wayne, PA: NCCLS, 2000.
  • 9
    Johnson JR, O'Bryan TT. Improved repetitive-element PCR fingerprinting for resolving pathogenic and non-pathogenic phylogenetic groups within Escherichia coli. Clin Diagn Lab Immunol 2000; 7: 265273.
  • 10
    Everett MJ, Jin YF, Ricci V, Piddock LJ. Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrob Agents Chemother 1996; 40: 23802386.
  • 11
    Carratala J, Fernandez-Sevilla A, Tubau F, Callis M, Gudiol F. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 1995; 20: 557560.
  • 12
    Dupeyron C, Mangeney N, Sedrati L, Campillo B, Fouet P, Leluan G. Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis. Antimicrob Agents Chemother 1994; 38: 340344.
  • 13
    Horcajada JP, Vila J, Moreno-Martinez A et al. Molecular epidemiology and evolution of resistance to quinolones in Escherichia coli after prolonged administration of ciprofloxacin in patients with prostatitis. J Antimicrob Chemother 2002; 49: 5559.